Inventor · disambiguated record
Ward M. Peterson
Also filed as: PETERSON WARD · PETERSON WARD M
22 granted patents·14 pending applications·451 citations·filing 2000–2024
96Inventor score
Top patents by PatentIndex Score
36 records- 0196US7531525B2P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosisINSPIRE PHARMACEUTICALS INC·Filed 2007·Granted May 12, 2009·21 cites·5 claims
- 0293US8207195B2Method for treating neurological and neuropathic diseases using rho kinase inhibitor compoundsNAVRATIL TOMAS·Filed 2009·Granted Jun 26, 2012·37 cites·7 claims
- 0393US7223744B2Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereofINSPIRE PHARMACEUTICALS INC·Filed 2004·Granted May 29, 2007·34 cites·32 claims
- 0493US6818629B2Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphateINSPIRE PHARMACEUTICALS INC·Filed 2003·Granted Nov 16, 2004·57 cites·8 claims
- 0593US6596725B2Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edemaINSPIRE PHARMACEUTICALS INC·Filed 2001·Granted Jul 22, 2003·52 cites·34 claims
- 0692US8299096B2Method for treating pulmonary diseases using rho kinase inhibitor compoundsNAVRATIL TOMAS·Filed 2009·Granted Oct 30, 2012·33 cites·17 claims
- 0792US8071779B2Cytoskeletal active rho kinase inhibitor compounds, composition and useLAMPE JOHN W·Filed 2007·Granted Dec 6, 2011·36 cites·19 claims
- 0891US8410147B2Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compoundsPETERSON WARD M·Filed 2009·Granted Apr 2, 2013·28 cites·9 claims
- 0990US6624150B2Method of treating gastrointestinal tract disease with purinergic receptor agonistsINSPIRE PHARMACEUTICALS INC·Filed 2000·Granted Sep 23, 2003·35 cites·13 claims
- 1086US6730707B2Method for reducing intraocular pressure using indole derivativesINSPIRE PHARMACEUTICALS INC·Filed 2001·Granted May 4, 2004·29 cites·24 claims
- 1183US7435724B2Degradation-resistant mononucleoside phosphate compoundsINSPIRE PHARMACEUTICAL INC·Filed 2005·Granted Oct 14, 2008·10 cites·21 claims
- 1283US7084128B2Method for reducing intraocular pressureINSPIRE PHARMACEUTICALS INC·Filed 2003·Granted Aug 1, 2006·19 cites·27 claims
- 1380US6881725B2Method for treating painINSPIRE PHARMACEUTICALS INC·Filed 2003·Granted Apr 19, 2005·16 cites·26 claims
- 1479US7115585B2Compositions for treating epithelial and retinal tissue diseasesINSPIRE PHARMACEUTICALS INC·Filed 2002·Granted Oct 3, 2006·13 cites·7 claims
- 1579US6864243B1Method for treating retinal degeneration with purinergic receptor agonistsINSPIRE PHARMACEUTICALS INC·Filed 2000·Granted Mar 8, 2005·10 cites·21 claims
- 1675US7078391B2Method of treating edematous retinal disordersINSPIRE PHARMACEUTICALS INC·Filed 2003·Granted Jul 18, 2006·13 cites·20 claims
- 1773US12017994B2Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrheaSYMBERIX INC·Filed 2018·Granted Jun 25, 2024·1 cites·12 claims
- 1873US7256183B2Method for treating or preventing inflammatory diseasesINSPIRE PHARMACEUTICALS INC·Filed 2002·Granted Aug 14, 2007·6 cites·18 claims
- 1969US8008274B2P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitisINSPIRE PHARMACEUTICALS INC·Filed 2009·Granted Aug 30, 2011·0 cites·3 claims
- 2068US8604218B2Cytoskeletal active rho kinase inhibitor compounds, composition and useLAMPE JOHN W·Filed 2011·Granted Dec 10, 2013·1 cites·20 claims
- 2167US2024417377A1COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEASYMBERIX INC·Filed 2024·Application pending·0 cites
- 2265US7612047B2Degradation-resistant mononucleoside phosphate compoundsINSPIRE PHARMACEUTICALS INC·Filed 2008·Granted Nov 3, 2009·0 cites·6 claims
- 2361US2010008968A1Method for treating cardiovascular diseases using rho kinase inhibitor compoundsLAMPE JOHN W·Filed 2009·Application pending·0 cites
- 2461US2009325959A1Method for treating ophthalmic diseases using rho kinase inhibitor compoundsVITTITOW JASON L·Filed 2009·Application pending·0 cites
- 2561US2009325960A1Method for treating inflammatory diseases using rho kinase inhibitor compoundsFULCHER EMILEE H·Filed 2009·Application pending·0 cites
- 2657US2013172324A1Method for treating cardiovascular diseases using rho kinase inhibitor compoundsINSPIRE PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2756US2013158014A1Method for treating diseases associated with alterations in cellular integrity using rho kinase inhibitor compoundsINSPIRE PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2853US8604205B2Cytoskeletal active rho kinase inhibitor compounds, composition and useLAMPE JOHN W·Filed 2012·Granted Dec 10, 2013·0 cites·20 claims
- 2953US2005009778A1Method for treating retinal degeneration with purinergic receptor agonistsFiled 2004·Application pending·0 cites
- 3053US2009098064A1Method of treating pulmonary edema or pulmonary inflammationNAVRATIL TOMAS·Filed 2007·Application pending·0 cites
- 3153US2023000894A1Treating mitochondrial dna depletion disordersMITORAINBOW THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3251US2010022517A1Ophthalmic formulation of rho kinase inhibitor compoundRICHARDS LORI A·Filed 2009·Application pending·0 cites
- 3347US2004198803A1Method for reducing intraocular pressure using indole derivativesFiled 2004·Application pending·0 cites
- 3445US2013005756A1Method for treating pulmonary diseases using rho kinase inhibitor compoundsNAVRATIL TOMAS·Filed 2012·Application pending·0 cites
- 3542US2013131106A1Bifunctional rho kinase inhibitor compounds, composition and useINSPIRE PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3641US2022125778A1Compounds, compositions, and methods for selectively inhibiting beta-glucuronidases and alleviating side effects associated with drug treatment induced diarrheaSYMBERIX INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →